TORONTO, Ontario — December 15, 2025 — Leads & Copy — Revive Therapeutics Ltd. is collaborating with Defence R&D Canada – Suffield Research Centre to study Bucillamine as a potential treatment for nerve agent exposure.
The research study is expected to conclude in January 2026, with findings released upon DRDC authorization. Revive Therapeutics is focused on developing therapeutics for infectious diseases and medical countermeasures.
Revive is also exploring Bucillamine for long COVID and advancing the development of Psilocybin and molecular hydrogen therapeutics.
For more information, please contact: Michael Frank, Chief Executive Officer, Revive Therapeutics Ltd. Tel: 1 888 901 0036 Email: mfrank@revivethera.com
Source: Revive Therapeutics Ltd.
